Savara's Phase 3 IMPALA-2 Trial Of Molgramostim Met Statistical Significance For Primary Endpoint And Multiple Secondary Endpoints In Autoimmune Pulmonary Alveolar Proteinosis
Portfolio Pulse from Benzinga Newsdesk
Savara's Phase 3 IMPALA-2 trial of Molgramostim met statistical significance for primary and multiple secondary endpoints in treating autoimmune pulmonary alveolar proteinosis. The company plans to complete BLA submission in the first half of 2025.
June 26, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Savara's Phase 3 IMPALA-2 trial of Molgramostim met statistical significance for primary and multiple secondary endpoints, showing promise in treating autoimmune pulmonary alveolar proteinosis. The company plans to complete BLA submission in the first half of 2025.
The successful Phase 3 trial results for Molgramostim, meeting both primary and secondary endpoints, are likely to boost investor confidence in Savara. The planned BLA submission in 1H 2025 further adds to the positive outlook, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100